<p>FreeGulliver LLC 在第二季度購買了 MDxHealth SA (NASDAQ:MDXH - 免費報告) 的新股份，根據其最近向 SEC 提交的 13F 表格。該機構投資者購買了 123,546 股公司股票，價值約 273,000 美元。FreeGulliver LLC 在最近一個季度末擁有 MDxHealth 約 0.26% 的股份。</p>
<p>另外，AWM Investment Company Inc. 在第一季度將其在 MDxHealth 的股份提高了 10.6%。AWM Investment Company Inc. 目前擁有 5,221,282 股公司股票，價值 7,414,000 美元，此前在上個季度購買了額外的 499,992 股。</p>
<h2>MDxHealth 價格表現</h2>
<p>NASDAQ MDXH 週二開盤價為 3.57 美元。該公司的債務與股本比率為 13.81，流動比率為 1.31，速動比率為 1.22。該公司的市值為 1.6882 億美元，市盈率為 -4.06，貝塔係數為 1.68。該公司有 50 日簡單移動平均線為 4.28 美元，200 日簡單移動平均線為 3.14 美元。MDxHealth SA 的 52 周低點為 1.35 美元，52 周高點為 5.33 美元。</p>
<p>MDxHealth (NASDAQ:MDXH - 獲取免費報告) 最近一次發佈財報是在 11 月 12 日星期三。該公司報告本季度每股收益（EPS）為 -0.16，低於分析師的共識預期（-0.12）0.04 美元。MDxHealth 的股本回報率為 -374.98%，淨利潤率為 -34.98%。該公司本季度的收入為 2743 萬美元，而分析師的預期為 2411 萬美元。MDxHealth 已設定其 2025 財年的每股收益指導。股票研究分析師預測 MDxHealth SA 本財年的每股收益將為 -1.15。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些券商最近對 MDXH 發佈了報告。華爾街 Zen 在 8 月 30 日星期六的報告中將 MDxHealth 的評級上調至 “持有”。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 MDxHealth 股票的 “賣出（e+）” 評級。TD Cowen 在 11 月 13 日星期四的研究報告中將 MDxHealth 股票的目標價從 5.00 美元上調至 7.00 美元，並給予該股票 “買入” 評級。BTIG Research 在 11 月 13 日星期四的報告中將 MDxHealth 股票的目標價從 6.00 美元上調至 7.00 美元，並給予該公司 “買入” 評級。最後，Lake Street Capital 在 11 月 13 日星期四的研究報告中將 MDxHealth 股票的目標價從 7.00 美元上調至 9.00 美元，並給予該股票 “買入” 評級。四位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，MDxHealth 目前的平均評級為 “適度買入”，共識目標價為 7.75 美元。</p>
<p><strong>閲讀我們最新的 MDXH 股票分析</strong></p>
<h2>關於 MDxHealth</h2>
<p>(免費報告)</p>
<p>MDxHealth SA 是一家商業階段的精準診斷公司，在美國、歐洲及國際市場提供泌尿科解決方案。其檢測解決方案包括 Select mdx，一種用於前列腺癌的非侵入性尿液檢測，測量兩種與癌症相關的 mRNA 生物標誌物的表達；Confirm mdx 用於前列腺癌組織檢測，驗證指導檢測患者先前活檢陰性組織中隱匿前列腺癌的表觀遺傳學檢測；以及 Resolved mdx 用於尿路感染，識別針對患者感染的個性化有效抗生素選擇。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MDxHealth</li>
<li>股票情緒分析：如何運作</li>
<li>5 只零售股票可能會裝點節日——或毀掉投資組合</li>
<li>REIT 股票 - 今天添加到您投資組合中的最佳 REIT 股票</li>
<li>D-Wave：是時候買入了嗎？還是下跌才剛剛開始？</li>
<li>在經濟衰退中與這些股息之王共度難關</li>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MDxHealth 嗎？</h2>
<p>在考慮 MDxHealth 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 MDxHealth 並不在名單上。</p>
<p>雖然 MDxHealth 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXH

<p>FreeGulliver LLC 根據其最新的 SEC 文件收購了 123,546 股 MDxHealth SA，估值約為 273,000 美元。這筆購買代表了 MDxHealth 約 0.26% 的股權。該公司的股票表現和財務指標也進行了討論，包括最近的財報和分析師評級。MDxHealth 的評級為適度買入，市場共識目標價為 7.75 美元。該公司專注於泌尿科解決方案的精準診斷</p>

<p>FreeGulliver LLC purchased a new stake in MDxHealth SA (NASDAQ:MDXH - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 123,546 shares of the company's stock, valued at approximately $273,000. FreeGulliver LLC owned about 0.26% of MDxHealth at the end of the most recent quarter.</p>
<div class="lb-trans"><p>FreeGulliver LLC 在第二季度購買了 MDxHealth SA (NASDAQ:MDXH - 免費報告) 的新股份，根據其最近向 SEC 提交的 13F 表格。該機構投資者購買了 123,546 股公司股票，價值約 273,000 美元。FreeGulliver LLC 在最近一個季度末擁有 MDxHealth 約 0.26% 的股份。</p>
</div><p>Separately, AWM Investment Company Inc. lifted its stake in MDxHealth by 10.6% during the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock valued at $7,414,000 after purchasing an additional 499,992 shares during the last quarter.</p>
<div class="lb-trans"><p>另外，AWM Investment Company Inc. 在第一季度將其在 MDxHealth 的股份提高了 10.6%。AWM Investment Company Inc. 目前擁有 5,221,282 股公司股票，價值 7,414,000 美元，此前在上個季度購買了額外的 499,992 股。</p>
</div><h2>MDxHealth Price Performance</h2>
<div class="lb-trans"><h2>MDxHealth 價格表現</h2>
</div><p>NASDAQ MDXH opened at $3.57 on Tuesday. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.31 and a quick ratio of 1.22. The firm has a market capitalization of $168.82 million, a price-to-earnings ratio of -4.06 and a beta of 1.68. The company has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $3.14. MDxHealth SA has a 52-week low of $1.35 and a 52-week high of $5.33.</p>
<div class="lb-trans"><p>NASDAQ MDXH 週二開盤價為 3.57 美元。該公司的債務與股本比率為 13.81，流動比率為 1.31，速動比率為 1.22。該公司的市值為 1.6882 億美元，市盈率為 -4.06，貝塔係數為 1.68。該公司有 50 日簡單移動平均線為 4.28 美元，200 日簡單移動平均線為 3.14 美元。MDxHealth SA 的 52 周低點為 1.35 美元，52 周高點為 5.33 美元。</p>
</div><p>MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The company had revenue of $27.43 million during the quarter, compared to analysts' expectations of $24.11 million. MDxHealth has set its FY 2025 guidance at EPS. Equities research analysts predict that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MDxHealth (NASDAQ:MDXH - 獲取免費報告) 最近一次發佈財報是在 11 月 12 日星期三。該公司報告本季度每股收益（EPS）為 -0.16，低於分析師的共識預期（-0.12）0.04 美元。MDxHealth 的股本回報率為 -374.98%，淨利潤率為 -34.98%。該公司本季度的收入為 2743 萬美元，而分析師的預期為 2411 萬美元。MDxHealth 已設定其 2025 財年的每股收益指導。股票研究分析師預測 MDxHealth SA 本財年的每股收益將為 -1.15。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages recently issued reports on MDXH. Wall Street Zen upgraded MDxHealth to a &#34;hold&#34; rating in a report on Saturday, August 30th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of MDxHealth in a report on Wednesday, October 8th. TD Cowen lifted their target price on shares of MDxHealth from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, November 13th. BTIG Research boosted their price target on shares of MDxHealth from $6.00 to $7.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 13th. Finally, Lake Street Capital raised their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, MDxHealth presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $7.75.</p>
<div class="lb-trans"><p>一些券商最近對 MDXH 發佈了報告。華爾街 Zen 在 8 月 30 日星期六的報告中將 MDxHealth 的評級上調至 “持有”。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 MDxHealth 股票的 “賣出（e+）” 評級。TD Cowen 在 11 月 13 日星期四的研究報告中將 MDxHealth 股票的目標價從 5.00 美元上調至 7.00 美元，並給予該股票 “買入” 評級。BTIG Research 在 11 月 13 日星期四的報告中將 MDxHealth 股票的目標價從 6.00 美元上調至 7.00 美元，並給予該公司 “買入” 評級。最後，Lake Street Capital 在 11 月 13 日星期四的研究報告中將 MDxHealth 股票的目標價從 7.00 美元上調至 9.00 美元，並給予該股票 “買入” 評級。四位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，MDxHealth 目前的平均評級為 “適度買入”，共識目標價為 7.75 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on MDXH</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 MDXH 股票分析</strong></p>
</div><h2>About MDxHealth</h2>
<div class="lb-trans"><h2>關於 MDxHealth</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.</p>
<div class="lb-trans"><p>MDxHealth SA 是一家商業階段的精準診斷公司，在美國、歐洲及國際市場提供泌尿科解決方案。其檢測解決方案包括 Select mdx，一種用於前列腺癌的非侵入性尿液檢測，測量兩種與癌症相關的 mRNA 生物標誌物的表達；Confirm mdx 用於前列腺癌組織檢測，驗證指導檢測患者先前活檢陰性組織中隱匿前列腺癌的表觀遺傳學檢測；以及 Resolved mdx 用於尿路感染，識別針對患者感染的個性化有效抗生素選擇。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than MDxHealth</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>5 Retail Stocks That Could Deck the Halls—or Wreck Portfolios</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MDxHealth</li>
<li>股票情緒分析：如何運作</li>
<li>5 只零售股票可能會裝點節日——或毀掉投資組合</li>
<li>REIT 股票 - 今天添加到您投資組合中的最佳 REIT 股票</li>
<li>D-Wave：是時候買入了嗎？還是下跌才剛剛開始？</li>
<li>在經濟衰退中與這些股息之王共度難關</li>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MDxHealth Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MDxHealth 嗎？</h2>
</div><p>Before you consider MDxHealth, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MDxHealth 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 MDxHealth 並不在名單上。</p>
</div><p>While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MDxHealth 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

FreeGulliver LLC 購入了 123,546 股 MDxHealth SA $MDXH 的股票